Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 9/20 | 0.60 |
| ▸ | MELK | Q14680 | 3/20 | 0.52 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.44 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FER | P16591 | 1/20 | 0.42 |
| ▸ | MATK | P42679 | 1/20 | 0.42 |
| ▸ | BLK | P51451 | 1/20 | 0.42 |
| ▸ | BMX | P51813 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.42 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.42 |
| ▸ | CAMK1 | Q14012 | 1/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17829606 | 0.93 | CCR4 (0.58) | CCR4MELKCACNA2D1 | |
| SCHEMBL17829974 | 0.88 | CCR4 (0.58) | CCR4MELKCACNA2D1 | |
| SCHEMBL17829643 | 0.84 | CCR4 (0.61) | CCR4MELK | |
| SCHEMBL17829670 | 0.77 | CCR4 (0.61) | CCR4CACNA2D1 | |
| SCHEMBL17829855 | 0.77 | CCR4 (0.63) | CCR4MELKCACNA2D1 | |
| SCHEMBL17829664 | 0.76 | CCR4 (0.62) | CCR4CACNA2D1 | |
| SCHEMBL17830140 | 0.76 | CCR4 (0.54) | CCR4CACNA2D1 | |
| SCHEMBL17831897 | 0.75 | CCR4 (0.44) | CCR4CACNA2D1 | |
| SCHEMBL17829625 | 0.75 | SIGMAR1 (0.44) | FGFR1 | |
| SCHEMBL17829678 | 0.74 | CCR4 (0.54) | CCR4MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | CCR4 4472/4885MELK 1849/4885CACNA2D1 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.